

Administration

PATIENT GROUP DIRECTION (PGD) FOR

CEFTRIAZONE 1g (1000mg) Injection

YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT

Clinical Condition	
Indication	First line treatment for uncomplicated gonococcal infection Treatment of patients who say they are over 16 years old attending Sexual Health Service supported clinics in Worcestershire diagnosed with uncomplicated gonococcal infection.
Inclusion criteria	Direct microscopic visualisation of N. Gonorrhoea as a monomorphic gram negative intracellular diplococci or on epidemiological grounds, if a sexual partner has been diagnosed with a gonococcal infection which is known to be sensitive to ceftriaxone Gonorrhoea positive laboratory results
Exclusion criteria If any of the following apply the PGD CANNOT be used and the patient must be referred to a prescriber	Known allergy to cephalosporins or penicillin or local anaesthetics Impaired cardiac function, bradycardia, hypovolaemia due to lidocaine diluent Individuals taking probenecid Complications such as suspected pelvic inflammatory disease, epidymo-orchitis Pregnancy or breast-feeding there are no adequate studies of safety but ceftriaxone not known to be harmful. Lidocaine is not recommended in early pregnancy or during breast feeding. Concurrent oral anticoagulants may lead to increased bleeding, INR should be monitored closely during and after treatment with ceftriaxone and oral anticoagulant dose adjusted accordingly (this will require a prescriber).
Cautions - Seek further advice from doctor before proceeding and document advice	If the patient is known to be under 16 the nurse will discuss treatment with a doctor before proceeding. Severe liver or renal dysfunction Should be given with caution to patients who have other allergic conditions
Action if excluded	Refer to prescriber

Administration

PATIENT GROUP DIRECTION (PGD) FOR





CEFTRIAZONE 1g (1000mg) Injection

Drug Details	
Name, form & strength of medicine	Ceftriaxone 250mg vials or single 1g vial
Legal status	Prescription Only Medicine (POM)
Route/Method	Deep intramuscular injection Should not be mixed in the same syringe with any drug other than 1.06% Lidocaine Hydrochloride BP solution (for intramuscular injection only). Contents of each vial should be dissolved in Lidocaine Hydrochloride BP solution as per manufacturers instructions
Dosage	1g (1000mg)
Frequency	Single dose
Quantity to administer	1000mg
Side effects	Most side-effects are mild and self-limiting and include: Rash, Itching, Diarrhoea, nausea, vomiting, headache, dizziness which may affect ability to drive and operate machinery
Advice to patient/carer	Advise patient to refer to the manufacturer's patient information leaflet and to attend for a test of cure 2 weeks after treatment and to abstain from sexual intercourse until after the test of cure confirms successful therapy and their partner(s) have completed treatment. Discuss risk reduction. Current recommendations are that no additional contraceptive precautions are required when <i>combined</i> oral contraceptives are used with antibacterials that do not induce liver enzymes, unless diarrhoea or vomiting occur.
Follow up	A contact slip for each traceable sexual partner who may also be infected will be given and/or provider-initiated contact tracing will be carried out and action documented

Administration

PATIENT GROUP DIRECTION (PGD) FOR

CEFTRIAZONE 1g (1000mg) Injection

Staff Characteristics	
Professional qualifications	Nurses on the NMC Register
Specialist competencies or qualifications	After discussion with and approval of departmental lead:- Individual should be trained in Genito-urinary Medicine (GUM) approved or provided by the Sexual Health Directorate. Attend updates on GUM / STI at least every 2 years and Have up to date anaphylaxis training and be competent to work under PGDs (completed online training package).
Continuing education & training	It is the responsibility of the individual to keep up-to-date with clinical developments as part of their continued professional development.
Referral Arrangements and Audit Trail	
Records/audit trail	Patient's name, address, date of birth, Contact details of GP (if registered), Diagnosis, Form administered, batch details and expiry, Advice given to patient (including side effects), Signature/name of staff who administered the medication, Details of any adverse drug reaction and actions taken including documentation in the patient's medical record, Referral arrangements (including self-care)
References/Resources and comments	Current versions of : National guidelines on the diagnosis and treatment of gonorrhoea in adults; County antibiotic guidelines, Summary of Product Characteristics, British National Formulary
Clinical Authorisation	
Lead Doctor	Dr Bill Spice, Consultant in GUM Signature:  Date: 25/01/2019
Lead Pharmacist	Dr Alex Johnson, Prescribing Support Pharmacist Signature:  Date: 6.2.19
Lead Nurse	Carolyn Gosling, GUM Specialist Nurse Signature:  Date: 30.01.2019
Organisational Authorisation	
On behalf of Worcestershire Health and Care NHS Trust	Michelle Clarke, Director of Nursing & Quality Signature:  Date: 4/2/19

